Technical Analysis for GTHX - G1 Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Calm After Storm | Range Contraction | -3.21% | |
| Wide Bands | Range Expansion | -3.21% | |
| New Uptrend | Bullish | -3.41% | |
| Calm After Storm | Range Contraction | -3.41% | |
| Wide Bands | Range Expansion | -3.41% | |
| Gapped Up | Strength | -3.41% | |
| Calm After Storm | Range Contraction | -2.58% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 1 day ago |
| Possible NR7 | 1 day ago |
| Fell Below 10 DMA | 1 day ago |
| 10 DMA Support | 2 days ago |
| Down 3% | 2 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/13/2024
G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Treatment Of Breast Cancer Protein Kinase Inhibitor Hormones Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Fulvestrant
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Treatment Of Breast Cancer Protein Kinase Inhibitor Hormones Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Fulvestrant
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.14 |
| 52 Week Low | 1.08 |
| Average Volume | 1,421,776 |
| 200-Day Moving Average | 2.77 |
| 50-Day Moving Average | 4.18 |
| 20-Day Moving Average | 4.32 |
| 10-Day Moving Average | 4.57 |
| Average True Range | 0.37 |
| RSI (14) | 53.92 |
| ADX | 27.23 |
| +DI | 35.71 |
| -DI | 16.29 |
| Chandelier Exit (Long, 3 ATRs) | 5.02 |
| Chandelier Exit (Short, 3 ATRs) | 4.64 |
| Upper Bollinger Bands | 5.01 |
| Lower Bollinger Band | 3.63 |
| Percent B (%b) | 0.65 |
| BandWidth | 32.02 |
| MACD Line | 0.14 |
| MACD Signal Line | 0.12 |
| MACD Histogram | 0.0233 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.82 | ||||
| Resistance 3 (R3) | 4.84 | 4.77 | 4.77 | ||
| Resistance 2 (R2) | 4.77 | 4.69 | 4.76 | 4.76 | |
| Resistance 1 (R1) | 4.65 | 4.65 | 4.61 | 4.63 | 4.74 |
| Pivot Point | 4.57 | 4.57 | 4.55 | 4.56 | 4.57 |
| Support 1 (S1) | 4.45 | 4.50 | 4.42 | 4.43 | 4.32 |
| Support 2 (S2) | 4.38 | 4.45 | 4.37 | 4.30 | |
| Support 3 (S3) | 4.26 | 4.38 | 4.29 | ||
| Support 4 (S4) | 4.24 |
